The UK and US have finalized a major commercial pact that will preserve zero duties on UK drug exports going into the American market.
Agreement Details of the Pact
In exchange for the tariff guarantee, the UK has committed to boost expenditure on medicines through the public health system. This move guarantees that duties on these key exports will remain at nothing for a duration of the next three years.
This agreement comes after recent statements to significantly raise import taxes on patented drug products, with increases discussed as high as double the cost.
"This agreement between the Britain reinforces the international landscape for innovative medicines and establishes long-overdue fairness to American-British pharmaceutical trade," a release declared.
Commercial Significance
Drugs are one of the UK's biggest exports to the US, which is by far the biggest destination for major UK drugmakers.
Statistics reveal that in the one-year period leading up to September, the UK sold medicines worth over eleven billion pounds to the US. This figure made up a significant portion of all goods exports in that span.
"This guarantee secures work, boosts funding and facilitates the UK to become a global hub for medical research," the Business and Trade Secretary stated.
Detailed British Pledges
The pact includes several specific commitments from the British government:
- Revised Affordability Limit: The UK will raise the price threshold at which it considers new medicines to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a target to raise overall public funding on drugs from 0.3 percent of the national economy to 0.6% over the next decade.
- Rebate Cap: The sum pharmaceutical firms must return to the NHS to stay within budget will be limited at fifteen percent. In the past, rebates exceeded twenty percent.
Recent Tensions
The pact takes place against a long-running row between the drug companies and the ministers over medicine costs and approval rates.
These tensions were exacerbated by assertions that American customers were charged significantly more for the identical medicines than patients in the Britain and the EU.
Over the last 18 months, several significant drug company projects in the UK have been delayed or abandoned, while major expansions have been pledged toward projects in the United States.
One official publicly accepted that the NHS had to spend more on drugs, noting that its budget allocation on drugs had declined as a percentage of its overall budget over the past decade.
